Home › Funds › a16z Capital Management, L.L.C. › DNA
a16z Capital Management, L.L.C. position in DNA
GINKGO BIOWORKS HOLDINGS INC · Health Care
a16z Capital Management, L.L.C. reported holding 108,568 shares of DNA (GINKGO BIOWORKS HOLDINGS INC) in its Q2 2026 13F filing — a position valued at US$1.1M, representing 0.01% of its reported portfolio and ranking #18 among its reported holdings. a16z Capital Management, L.L.C. has disclosed DNA holdings in 10 of the last 10 reported quarters, going back to Q1 2024.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How a16z Capital Management, L.L.C.'s DNA position evolved
a16z Capital Management, L.L.C. first disclosed a stake in DNA in Q1 2024 at 4,342,749 shares (US$5.0M). Across 10 filings, a16z Capital Management, L.L.C. increased the stake 0 time(s), trimmed it 1 time(s) and left it unchanged 8 time(s). The most recent filing (Q2 2026) shows 108,568 shares valued at US$1.1M. Notable position changes include a 98% trim in Q3 2024 (shares rose 20% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q1 2024 | 4.34M | $5.04M | New |
| Q2 2024 | 4.34M | $1.45M | Hold |
| Q3 2024 | 108.57K | $884.83K | Reduce |
| Q4 2024 | 108.57K | $1.07M | Hold |
| Q1 2025 | 108.57K | $618.84K | Hold |
| Q2 2025 | 108.57K | $1.22M | Hold |
| Q3 2025 | 108.57K | $1.58M | Hold |
| Q4 2025 | 108.57K | $902.20K | Hold |
| Q1 2026 | 108.57K | $665.52K | Hold |
| Q2 2026 | 108.57K | $1.08M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About DNA and 13F data
DNA (GINKGO BIOWORKS HOLDINGS INC) is a Health Care company. 33 other funds we track also report a position in DNA — the largest reported positions include Anchorage Capital Group, L.L.C. (US$17.3M), FORBES J M & CO LLP (US$12.5M), SB INVESTMENT ADVISERS (UK) LTD (US$6.1M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding DNA
- Anchorage Capital Group, L.L.C. 1.75M sh · $17.31M · Q2 2026
- FORBES J M & CO LLP 977.37K sh · $12.54M · Q3 2026
- SB INVESTMENT ADVISERS (UK) LTD 610.73K sh · $6.05M · Q2 2026
More on a16z Capital Management, L.L.C.
FAQ
How long has a16z Capital Management, L.L.C. held DNA?
a16z Capital Management, L.L.C. has disclosed DNA holdings in 10 of the last 10 reported quarters, going back to Q1 2024.
What is a16z Capital Management, L.L.C.'s current position in DNA?
As of Q2 2026, a16z Capital Management, L.L.C. holds 108.57K shares of DNA (GINKGO BIOWORKS HOLDINGS INC), valued at $1.08M, representing 0.01% of its reported portfolio and ranking #18.
Has a16z Capital Management, L.L.C. been buying or selling DNA?
In the latest 13F filing (Q2 2026), a16z Capital Management, L.L.C. held unchanged its position in DNA.
Which other funds hold DNA?
Other major institutional holders of DNA include Anchorage Capital Group, L.L.C., FORBES J M & CO LLP, SB INVESTMENT ADVISERS (UK) LTD, among 33 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.